Your browser doesn't support javascript.
loading
A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples.
Swank, Zoe; Michielin, Grégoire; Yip, Hon Ming; Cohen, Patrick; Andrey, Diego O; Vuilleumier, Nicolas; Kaiser, Laurent; Eckerle, Isabella; Meyer, Benjamin; Maerkl, Sebastian J.
Afiliación
  • Swank Z; Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • Michielin G; Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • Yip HM; Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • Cohen P; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, 1205 Geneva, Switzerland.
  • Andrey DO; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, 1205 Geneva, Switzerland.
  • Vuilleumier N; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, 1205 Geneva, Switzerland.
  • Kaiser L; Division of Laboratory Medicine, Department of Diagnostics, Geneva University Hospitals and Geneva University, 1205 Geneva, Switzerland.
  • Eckerle I; Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, 1205 Geneva, Switzerland.
  • Meyer B; Laboratory of Virology, Division of Laboratory Medicine, Geneva University Hospitals and Faculty of Medicine, 1205 Geneva, Switzerland.
  • Maerkl SJ; Center for Emerging Viral Diseases, Geneva University Hospitals and Faculty of Medicine, University of Geneva, 1205 Geneva, Switzerland.
Proc Natl Acad Sci U S A ; 118(18)2021 05 04.
Article en En | MEDLINE | ID: mdl-33945500
Novel technologies are needed to facilitate large-scale detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) specific antibodies in human blood samples. Such technologies are essential to support seroprevalence studies and vaccine clinical trials, and to monitor quality and duration of immunity. We developed a microfluidic nanoimmunoassay (NIA) for the detection of anti-SARS-CoV-2 IgG antibodies in 1,024 samples per device. The method achieved a specificity of 100% and a sensitivity of 98% based on the analysis of 289 human serum samples. To eliminate the need for venipuncture, we developed low-cost, ultralow-volume whole blood sampling methods based on two commercial devices and repurposed a blood glucose test strip. The glucose test strip permits the collection, shipment, and analysis of 0.6 µL of whole blood easily obtainable from a simple finger prick. The NIA platform achieves high throughput, high sensitivity, and specificity based on the analysis of 289 human serum samples, and negligible reagent consumption. We furthermore demonstrate the possibility to combine NIA with decentralized and simple approaches to blood sample collection. We expect this technology to be applicable to current and future SARS-CoV-2 related serological studies and to protein biomarker analysis in general.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prueba Serológica para COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Prueba Serológica para COVID-19 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Suiza Pais de publicación: Estados Unidos